<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00801333</url>
  </required_header>
  <id_info>
    <org_study_id>0511-08-HMO</org_study_id>
    <nct_id>NCT00801333</nct_id>
  </id_info>
  <brief_title>Derivation of Induced Pluripotent Stem Cells From an Existing Collection of Human Somatic Cells</brief_title>
  <official_title>Derivation of Induced Pluripotent Stem Cells From an Existing Collection of Human Somatic Cells</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hadassah Medical Organization</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hadassah Medical Organization</source>
  <brief_summary>
    <textblock>
      Induced pluripotent stem cells potentially may be useful in the future as an unlimited source&#xD;
      of cells for transplantation.&#xD;
&#xD;
      The major goal of the project is to develop human iPS cells from various types of cell&#xD;
      cultures or lines from existing collections. The IPS cells will be developed for modeling&#xD;
      diseases, for developing the technology that may eventually allow the use of IPS cells for&#xD;
      transplantation therapy, and for basic research.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The potential to reprogram somatic cells into an embryonic state raises multiple basic&#xD;
      research questions related both to the process of reprogramming and the properties of iPS&#xD;
      cells. We will use various approaches to study the molecular mechanisms and processes that&#xD;
      occur during reprogramming. We will use various experimental systems to characterize and&#xD;
      study the properties of the iPS cells, their biology, developmental potential, capability to&#xD;
      give rise to functional differentiated progeny etc.&#xD;
&#xD;
      We will induce the differentiation of the iPS cells towards specific cell lineages and the&#xD;
      progeny can be used to study the pathogenesis of diseases. They will be used for developing&#xD;
      new therapeutic approaches and for high throughput screening of factors for potential toxic&#xD;
      or therapeutic effects.&#xD;
&#xD;
      All samples will be non-identified.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 2008</start_date>
  <completion_date type="Anticipated">December 2025</completion_date>
  <primary_completion_date type="Anticipated">December 2025</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Amyotrophic Lateral Sclerosis</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Existing banks of collected cells maintained.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        We will use human somatic cells from existing collections.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Volunteers&#xD;
&#xD;
          -  Male and Female&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Below the official age of consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Benjamin E Reubinoff, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chairman of Department of Obstetrics &amp; Gynecology/IVF, Hadassah Ein Kerem</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Benjamin E. Reubinoff, M.D. PhD.</last_name>
    <phone>011-972-2-677-4569</phone>
    <email>benjaminr@ekmd.huji.ac.il</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Shelly E Tannenbaum, MSQA</last_name>
    <phone>011-972-2-677-7945</phone>
    <email>stannenbaum@hadassah.org.il</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hadassah Medical Organization - Ein Kerem Campus</name>
      <address>
        <city>Jerusalem</city>
        <zip>91120</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hadas Lemberg, PhD</last_name>
      <phone>011-972-2-677-6095</phone>
      <email>Lhadas@hadassah.org.il</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hadassah Ein Kerem</name>
      <address>
        <city>Jerusalem</city>
        <zip>9112100</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Benjamin E Reubinoff, Professor</last_name>
      <phone>972-2-6776424/5</phone>
      <email>benr@hadassah.org.il</email>
    </contact>
    <contact_backup>
      <last_name>Shelly E Tannenbaum, MSQA</last_name>
      <phone>972-2-6777945</phone>
      <email>stannenbaum@hadassah.org.il</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <reference>
    <citation>Dimos JT, Rodolfa KT, Niakan KK, Weisenthal LM, Mitsumoto H, Chung W, Croft GF, Saphier G, Leibel R, Goland R, Wichterle H, Henderson CE, Eggan K. Induced pluripotent stem cells generated from patients with ALS can be differentiated into motor neurons. Science. 2008 Aug 29;321(5893):1218-21. doi: 10.1126/science.1158799. Epub 2008 Jul 31.</citation>
    <PMID>18669821</PMID>
  </reference>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>December 2, 2008</study_first_submitted>
  <study_first_submitted_qc>December 2, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 3, 2008</study_first_posted>
  <last_update_submitted>August 11, 2021</last_update_submitted>
  <last_update_submitted_qc>August 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hadassah Medical Organization</investigator_affiliation>
    <investigator_full_name>Benjamin Reubinoff</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>ALS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

